Cellectis (NASDAQ:CLLS) Releases Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• Cellectis beat earnings expectations: The biotechnology company reported a quarterly loss of $0.22 per share, $0.04 better than analysts’ consensus estimate of a $0.26 loss. However, revenue of $6.90 million fell short of the $11.05 million estimate.
• Shares remain under pressure: Cellectis stock rose to $2.84 in midday trading but remains below its 50-day and 200-day moving averages, with a 12-month range of $2.35 to $5.48. The company also reported negative profitability metrics, including a 102.34% net margin.
• Analyst sentiment is moderately bullish: Analysts have set an average price target of $7.00, with ratings including one Strong Buy, four Buys and one Sell. Institutional investors own approximately 63.9% of the company.

Cellectis (NASDAQ:CLLS - Get Free Report) issued its quarterly earnings results on Friday. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.04, Zacks reports. Cellectis had a negative return on equity of 82.92% and a negative net margin of 102.34%.The company had revenue of $6.90 million for the quarter, compared to analyst estimates of $11.05 million.

Cellectis Price Performance

Cellectis stock traded up $0.15 during midday trading on Friday, hitting $2.84. The company's stock had a trading volume of 24,095 shares, compared to its average volume of 16,107. Cellectis has a 12 month low of $2.35 and a 12 month high of $5.48. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $284.97 million, a PE ratio of -4.37 and a beta of 2.91. The stock's 50-day moving average price is $2.95 and its 200-day moving average price is $3.48.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CLLS. Citizens Jmp reiterated a "market outperform" rating and issued a $8.00 target price on shares of Cellectis in a research report on Tuesday, April 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Cellectis in a research report on Friday, July 17th. Finally, Barclays assumed coverage on shares of Cellectis in a research note on Thursday, May 28th. They issued an "overweight" rating and a $9.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Institutional Trading of Cellectis

A number of large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its holdings in shares of Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company's stock valued at $864,000 after buying an additional 168,038 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Cellectis in the 4th quarter worth $15,385,000. Global Retirement Partners LLC purchased a new position in Cellectis in the 4th quarter worth about $34,000. Millennium Management LLC raised its holdings in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock valued at $165,000 after acquiring an additional 22,080 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in shares of Cellectis during the third quarter valued at approximately $633,000. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source